EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs ( EAP ) in Germany, France, and United Kingdom

Sylvain Rheims iD, Bernhard J Steinhoff iD, Edouard Hirsch iD, Felix Rosenow, Arnaud Biraben, Rhys Thomas iD, Alessandro Lovera iD, Paola Lipone, Alessandro Comandini, Caroline Benoist, Elena Alvarez Baron, John Paul Leach und 2 weitere

Epilepsia Open · 2025-06 · 10 (3) · 736-748

DOI: 10.1002/epi4.70021 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia Open, online erschienen am 22.03.2025. Verfasst von Sylvain Rheims und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Lyon 1 University, Lyon, France. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Resistant Epilepsy, Carbamates, Chlorophenols. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Angelini Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Investigate real‐world outcomes in drug‐resistant epilepsy (DRE) patients treated with cenobamate as adjunctive treatment to other antiseizure medications (ASMs) within the Early Access Programs (EAP) in Germany, France, and the United Kingdom.

Methods

DRE adults with uncontrolled focal‐onset seizures were included from 19 hospitals participating in the EAP in this retrospective study. Data were sourced from clinical records. Participants were evaluated at baseline, 1 months, and 3 months from cenobamate start, and 3, 6, and 12 months after maintenance. The primary effectiveness endpoint was the 50% responder rate, defined as the reduction in seizure frequency ≥50%.

Results

Data were collected from 298 patients who received at least one dose of cenobamate; efficacy was evaluated on 216 patients with seizure data available. At baseline, the median epilepsy duration was 22.2 years, and 41.9% of patients had previous epilepsy surgery, including vagus nerve stimulation, with a median of nine previously failed ASMs. The median number of seizures/month was 8.8. After 3 months of maintenance, the 50% responder rate (primary endpoint) was 49.3%; the median percentage seizure reduction from baseline was 49.1%. A total of 100%, ≥90%, and ≥75% seizures reduction were reported in 13.6%, 20.0%, and 33.6% of patients, respectively. Both the responder rate and the median percentage seizure reduction steadily increased during the observation period. At 6‐month maintenance, the seizure‐free rate was 24.2%. The retention rate assessed by Kaplan–Meier decreased from 96.6% at 1‐month cenobamate start to 69.7% at 12‐month maintenance. Adverse Drug Reactions (ADRs) to cenobamate occurred in 30.9% of patients, with asthenia, dizziness, and somnolence being the most frequent; the majority were mild‐to‐moderate and resolved during the observation period; three patients (1.0%) experienced a total of seven serious ADRs, all during titration. Significance In this study, cenobamate demonstrated to be an effective option for people with uncontrolled epilepsy even after multiple failed ASMs or failure of epilepsy surgery. Plain Language Summary This study involved patients with drug‐resistant epilepsy, who had continued seizures despite using at least two antiseizure medications (ASMs). Patients received cenobamate (Ontozry) as epilepsy treatment during the Early Access Program (EAP) in France, Germany, and the United Kingdom. An EAP allows patients to receive promising new drugs under clinical supervision before they are commercially available. After 6 months from cenobamate start, 49.3% of patients had their seizures cut by half or more, and 13.6% became seizure‐free. A total of 30.9% of patients had an undesirable reaction to cenobamate, mostly mild‐to‐moderate and resolved; the most frequent were asthenia, dizziness, and somnolence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsDrug Resistant EpilepsyCarbamatesChlorophenolsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedFranceUnited KingdomTreatment OutcomeGermanyYoung AdultAgedTetrazoles

Stichwörter der Autor:innen

antiseizure medicationcenobamateresponder rateseizure freedom

Substanzen

AnticonvulsantsCenobamateCarbamatesChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Lyon 1 University, Lyon, France.
  • Lyon's Neuroscience Research Center, INSERM U1028/CNRS UMR 5292, Lyon 1 University, Lyon, France.
  • Epilepsy Institute, Lyon, France.
  • Department for Adults, Kork Epilepsy Center, Kehl-Kork, Germany.
  • Medical Faculty, University of Freiburg, Freiburg, Germany.
  • Francis Rohmer Neurology Epilepsy Units, National Institute of Health and Medical Research 1258, Federation of Translational Medicine of Strasbourg, Strasbourg University, Strasbourg, France.

ORCID-Profile: Sylvain Rheims, Bernhard J Steinhoff, Edouard Hirsch, Rhys Thomas, Alessandro Lovera

Förderung

  • Angelini Pharma

Zitieren

APA

Rheims, S., Steinhoff, B. J., Hirsch, E., Rosenow, F., Biraben, A., Thomas, R., Lovera, A., Lipone, P., Comandini, A., Benoist, C., Baron, E. A., Leach, J. P., Thangavelu, K., & Cattaneo, A. (2025). Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs ( EAP ) in Germany, France, and United Kingdom. Epilepsia Open, 10(3), 736-748. https://doi.org/10.1002/epi4.70021

Vancouver

Rheims S, Steinhoff BJ, Hirsch E, Rosenow F, Biraben A, Thomas R, et al. Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs ( EAP ) in Germany, France, and United Kingdom. Epilepsia Open. 2025;10(3):736-748. doi:10.1002/epi4.70021

BibTeX
@article{Rheims2025,
  author = {Rheims, Sylvain and Steinhoff, Bernhard J and Hirsch, Edouard and Rosenow, Felix and Biraben, Arnaud and Thomas, Rhys and Lovera, Alessandro and Lipone, Paola and Comandini, Alessandro and Benoist, Caroline and Baron, Elena Alvarez and Leach, John Paul and Thangavelu, Karthinathan and Cattaneo, Agnese},
  title = {Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs ( EAP ) in Germany, France, and United Kingdom},
  journal = {Epilepsia Open},
  year = {2025},
  volume = {10},
  number = {3},
  pages = {736--748},
  doi = {10.1002/epi4.70021}
}
Kostenlos starten →